一种减毒活嵌合西尼罗河病毒疫苗rWN/DEN4Δ30，在未感染黄病毒的老年志愿者中耐受性良好且具有免疫原性。
A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.
作者信息
Pierce Kristen K, Whitehead Stephen S, Kirkpatrick Beth D, Grier Palmtama L, Jarvis Adrienne, Kenney Heather, Carmolli Marya P, Reynolds Cynthia, Tibery Cecilia M, Lovchik Janece, Janiak Anna, Luke Catherine J, Durbin Anna P, Pletnev Alexander G
机构信息
Robert Larner MD College of Medicine at the University of Vermont, Burlington.
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda.
出版信息
J Infect Dis. 2017 Jan 1;215(1):52-55. doi: 10.1093/infdis/jiw501. Epub 2016 Oct 25.
Abstract
West Nile virus (WNV) is a major cause of mosquito-borne illness in the United States. Human disease ranges from mild febrile illness to severe fatal neurologic infection. Adults aged >60 years are more susceptible to neuroinvasive disease accompanied by a high mortality rate or long-lasting neurologic sequelae. A chimeric live attenuated West Nile virus vaccine, rWN/DEN4Δ30, was shown to be safe and immunogenic in healthy adults aged 18-50 years. This study evaluated rWN/DEN4Δ30 in flavivirus-naive adults aged 50-65 years and found it to be safe and immunogenic. Outbreaks of WNV infection tend to be unpredictable, and a safe and effective vaccine will be an important public health tool.
摘要
西尼罗河病毒（WNV）是美国蚊媒疾病的主要病因。人类疾病范围从轻度发热疾病到严重的致命性神经感染。60岁以上的成年人更容易患神经侵袭性疾病，伴有高死亡率或长期神经后遗症。一种嵌合减毒活西尼罗河病毒疫苗rWN/DEN4Δ30，在18至50岁的健康成年人中显示出安全且具有免疫原性。本研究评估了rWN/DEN4Δ30在50至65岁未感染黄病毒的成年人中的情况，发现它安全且具有免疫原性。西尼罗河病毒感染的爆发往往不可预测，一种安全有效的疫苗将是一项重要的公共卫生工具。
相似文献
1
A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.一种减毒活嵌合西尼罗河病毒疫苗rWN/DEN4Δ30，在未感染黄病毒的老年志愿者中耐受性良好且具有免疫原性。
J Infect Dis. 2017 Jan 1;215(1):52-55. doi: 10.1093/infdis/jiw501. Epub 2016 Oct 25.
2
The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.活减毒嵌合疫苗 rWN/DEN4Δ30 在健康的黄病毒初免成人志愿者中具有良好的耐受性和免疫原性。
Vaccine. 2013 Nov 19;31(48):5772-7. doi: 10.1016/j.vaccine.2013.07.064. Epub 2013 Aug 19.
3
Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.针对西尼罗河病毒的减毒活疫苗的神经毒性保证：与两种亲本病毒和一种黄病毒替代参考疫苗相比，对嵌合WN/DEN4Δ30疫苗感染后的神经发病机制进行的综合研究。
Vaccine. 2014 May 30;32(26):3187-97. doi: 10.1016/j.vaccine.2014.04.002. Epub 2014 Apr 13.
4
Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses.一种减毒西尼罗河病毒疫苗（活黄病毒嵌合体）在马体内的安全性。
Equine Vet J. 2007 Nov;39(6):486-90. doi: 10.2746/042516407X214473.
5
Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.西尼罗河病毒疫苗（活黄病毒嵌合体）在患有临床疾病挑战模型的马匹中的免疫原性效力、持续时间和起效时间。
Equine Vet J. 2007 Nov;39(6):491-7. doi: 10.2746/042516407X217416.
6
Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.西尼罗河病毒疫苗在 50 岁以上健康成年人中的单剂安全性和免疫原性的 II 期、剂量范围研究。
Vaccine. 2012 Oct 19;30(47):6656-64. doi: 10.1016/j.vaccine.2012.08.063. Epub 2012 Sep 7.
7
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.基于 YFV-17D 的嵌合疫苗在西尼罗河病毒防治中的临床前和临床研究进展。
Viruses. 2013 Dec 9;5(12):3048-70. doi: 10.3390/v5123048.
8
MicroRNA reduction of neuronal West Nile virus replication attenuates and affords a protective immune response in mice.微小RNA减少神经元中寨卡病毒的复制可减轻小鼠的症状并引发保护性免疫反应。
Vaccine. 2016 Oct 17;34(44):5366-5375. doi: 10.1016/j.vaccine.2016.08.063. Epub 2016 Sep 13.
9
Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.一项针对健康成年人的西尼罗河病毒疫苗的免疫原性和安全性的 II 期、随机、双盲、安慰剂对照、多中心研究。
J Infect Dis. 2011 Jan 1;203(1):75-84. doi: 10.1093/infdis/jiq003.
10
Vaccines in development against West Nile virus.针对西尼罗河病毒研发的疫苗。
Viruses. 2013 Sep 30;5(10):2384-409. doi: 10.3390/v5102384.
引用本文的文献
1
Immunity to Non-Dengue Flaviviruses Impacts Dengue Virus Immunoglobulin G Enzyme-Linked Immunosorbent Assay Specificity in Cambodia.对非登革热黄病毒的免疫影响柬埔寨登革病毒免疫球蛋白G酶联免疫吸附测定的特异性。
J Infect Dis. 2025 Feb 20;231(2):e337-e344. doi: 10.1093/infdis/jiae422.
2
Subgenomic flavivirus RNA as key target for live-attenuated vaccine development.亚基因组黄病毒 RNA 作为减毒活疫苗开发的关键靶标。
J Virol. 2024 Jul 23;98(7):e0010023. doi: 10.1128/jvi.00100-23. Epub 2024 May 29.
3
Characteristics of Chimeric West Nile Virus Based on the Japanese Encephalitis Virus SA14-14-2 Backbone.基于日本脑炎病毒 SA14-14-2 骨架的嵌合西尼罗河病毒的特征。
Viruses. 2021 Jun 29;13(7):1262. doi: 10.3390/v13071262.
4
A 20-year historical review of West Nile virus since its initial emergence in North America: Has West Nile virus become a neglected tropical disease?自西尼罗河病毒首次出现在北美洲以来的 20 年历史回顾：西尼罗河病毒是否已成为被忽视的热带病？
PLoS Negl Trop Dis. 2021 May 6;15(5):e0009190. doi: 10.1371/journal.pntd.0009190. eCollection 2021 May.
5
Pathogenicity and virulence of West Nile virus revisited eight decades after its first isolation.时隔西尼罗河病毒首次分离 80 年后再探其致病性和毒力。
Virulence. 2021 Dec;12(1):1145-1173. doi: 10.1080/21505594.2021.1908740.
6
Twenty Years of Progress Toward West Nile Virus Vaccine Development.西尼罗河病毒疫苗研发 20 年进展
Viruses. 2019 Sep 5;11(9):823. doi: 10.3390/v11090823.
7
Role of NS1 and TLR3 in Pathogenesis and Immunity of WNV.NS1 和 TLR3 在西尼罗河病毒发病机制和免疫中的作用。
Viruses. 2019 Jul 3;11(7):603. doi: 10.3390/v11070603.
8
West Nile virus vaccines - current situation and future directions.西尼罗河病毒疫苗——现状与未来方向。
Hum Vaccin Immunother. 2019;15(10):2337-2342. doi: 10.1080/21645515.2019.1621149. Epub 2019 Jul 10.
9
Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine.嵌合黄热 17D-Zika 病毒（ChimeriVax-Zika）作为一种减毒活 Zika 病毒疫苗。
Sci Rep. 2018 Sep 4;8(1):13206. doi: 10.1038/s41598-018-31375-9.
10
Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination.我们是否为欧洲出现的黄病毒做好了准备？疫苗接种面临的挑战。
Hum Vaccin Immunother. 2018 Feb 1;14(2):337-344. doi: 10.1080/21645515.2017.1389363. Epub 2017 Nov 29.
本文引用的文献
1
Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.针对西尼罗河病毒的减毒活疫苗的神经毒性保证：与两种亲本病毒和一种黄病毒替代参考疫苗相比，对嵌合WN/DEN4Δ30疫苗感染后的神经发病机制进行的综合研究。
Vaccine. 2014 May 30;32(26):3187-97. doi: 10.1016/j.vaccine.2014.04.002. Epub 2014 Apr 13.
2
Current trends in West Nile virus vaccine development.西尼罗河病毒疫苗研发的最新趋势。
Expert Rev Vaccines. 2014 May;13(5):589-608. doi: 10.1586/14760584.2014.906309. Epub 2014 Apr 1.
3
The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.活减毒嵌合疫苗 rWN/DEN4Δ30 在健康的黄病毒初免成人志愿者中具有良好的耐受性和免疫原性。
Vaccine. 2013 Nov 19;31(48):5772-7. doi: 10.1016/j.vaccine.2013.07.064. Epub 2013 Aug 19.
4
Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010.1999-2010 年美国成年人西尼罗河病毒感染的估计累积发病率。
Epidemiol Infect. 2013 Mar;141(3):591-5. doi: 10.1017/S0950268812001070. Epub 2012 May 28.
5
Evolution of new genotype of West Nile virus in North America.西尼罗河病毒新基因型在北美的演变。
Emerg Infect Dis. 2011 May;17(5):785-93. doi: 10.3201/eid1705.101707.
6
West Nile virus neuroinvasive disease incidence in the United States, 2002-2006.2002 - 2006年美国西尼罗河病毒神经侵袭性疾病发病率
Vector Borne Zoonotic Dis. 2008 Spring;8(1):35-9. doi: 10.1089/vbz.2007.0137.
7
Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.嵌合西尼罗河/登革病毒候选疫苗：在小鼠、鹅和猴子中进行的安全性和免疫原性临床前评估。
Vaccine. 2006 Sep 29;24(40-41):6392-404. doi: 10.1016/j.vaccine.2006.06.008. Epub 2006 Jun 21.
8
West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States.西尼罗河病毒：美国一场新出现的流行病的流行病学与临床特征
Annu Rev Med. 2006;57:181-94. doi: 10.1146/annurev.med.57.121304.131418.
9
Phylogenetic analysis of North American West Nile virus isolates, 2001-2004: evidence for the emergence of a dominant genotype.2001 - 2004年北美西尼罗河病毒分离株的系统发育分析：优势基因型出现的证据
Virology. 2005 Nov 25;342(2):252-65. doi: 10.1016/j.virol.2005.07.022. Epub 2005 Aug 31.
10
Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors.西尼罗河/登革嵌合病毒对西尼罗河和登革热蚊媒的感染性。
Vector Borne Zoonotic Dis. 2005 Spring;5(1):1-10. doi: 10.1089/vbz.2005.5.1.
Zotero 插件